All In Biotech

Drug Trial Radar · NCT03336333

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)

Last checked: Nov 20, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 590 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

590

Actual

Start

Oct 31, 2017

Primary completion

May 7, 2021

Study completion Oct 31, 2027

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Nov 8, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review.

Conditions

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Interventions

  • ZanubrutinibDrug

    Administered as two 80-milligram (mg) capsules by mouth twice a day (160 mg twice a day)

  • BendamustineDrug

    Administered intravenously (IV) at a dose of 90 mg/m\^2/day on the first 2 days of each cycle for 6 cycles.

  • RituximabDrug

    Administered intravenously (IV) at a dose of 375 mg/m\^2 on day 0 of cycle 1, and at a dose of 500 mg/m\^2 on day 1 of cycles 2 to 6

  • VenetoclaxDrug

    400 mg tablets administered orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Progression-free Survival (PFS) as Determined by Independent Central Review (ICR)Time frame: Up to approximately 3 years and 7 months (as of cut-off date of 07MAY2021)

Locations

158 sites in 15 countries. Site status is shown where the registry gives one.

  • Augusta University

    Augusta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Research Medical Center

    Kansas City, Missouri

  • Washington University

    St Louis, Missouri

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Summit Medical Group

    Florham Park, New Jersey

  • Icahn School of Medicine At Mount Sinai

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • University of Rochester

    Rochester, New York

  • Duke University

    Durham, North Carolina

  • Oregon Health and Science University

    Portland, Oregon

  • Prairie Lakes Healthcare System

    Watertown, South Dakota

  • Tennessee Oncology, Pllc Nashville

    Nashville, Tennessee

  • Joe Arrington Cancer Research and Treatment Center

    Lubbock, Texas

  • University of Virginia

    Charlottesville, Virginia

  • Va Puget Sound Health Care System

    Seattle, Washington

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia

  • The Tweed Valley Hospital

    Cudgen, New South Wales, Australia

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Icon Cancer Centre Wesley

    Auchenflower, Queensland, Australia

  • Princess Alexandra Hospital

    Brisbane, Queensland, Australia

  • Royal Brisbane and Womens Hospital

    Herston, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • The Queen Elizabeth Hospital

    Woodville South, South Australia, Australia

  • Royal Hobart Hospital

    Hobart, Tasmania, Australia

  • Box Hill Hospital

    Box Hill, Victoria, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • St Vincents Hospital Melbourne

    Fitzroy, Victoria, Australia

  • Peninsula Private Hospital

    Frankston, Victoria, Australia

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia

  • Royal Perth Hospital

    Perth, Western Australia, Australia

  • Medizinische Universitatsklinik Innsbruck

    Innsbruck, Austria

  • Krankenhaus Der Barmherzigen Schwestern Linz

    Linz, Austria

  • Allgemeines Krankenhaus Der Stadt Linz

    Linz, Austria

  • Universitatsklinik Fur Innere Medizin Iii Universitatsklinikum Der Pmu Landeskrankenhaus Salzburg

    Salzburg, Austria

  • Klinikum Wels Grieskirchen

    Wels, Austria

  • Universitair Ziekenhuis Brussel

    Brussels, Belgium

Showing 40 of 158 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.